The Zimmer medical instrument company is on trial in Los Angeles for $500,000 to develop brain tumor therapies that could be given as a pill or given intravenously.
Zimmer, based in New York, said Monday that it plans to develop a new type of injection, called an extracorporeal membrane implant, that would inject a drug into the body at the site of a tumor.
The drugs could be administered as a capsule, a gel, a syringe or a balloon.
The company has tested its technology on mice and monkeys, said Scott Zim, a Zimmer spokesman.
He declined to disclose the price.
The FDA approved the drug last month, with an estimated price tag of about $1,100 per dose.
Zim said the device could also be implanted in the head, where it could be used to treat conditions such as multiple sclerosis, Parkinson’s disease and glaucoma.
Zimmers medical instrument has been a major player in the medical device industry.
In recent years, it has developed the Zimmer M5 and Zimmer Pro 2, which offer more sophisticated designs, but lower prices.
The drugmaker also has plans to make a new kind of injection that would be a capsule rather than a gel or syringe, said Jason Hausman, a spokesman for Zimmer.
It would be injected directly into the brain, rather than through a vein, he said.
The implant would not need to be placed in the brain and could be inserted through a small hole in the skull, he added.
In September, Zimmer said it was testing a new drug, a cancer drug called ZZ-18, for use in humans.
Zimmer, like other companies, is trying to get into the cancer business with drug candidates.
The FDA has said it will not approve the drug until the drug is proven safe and effective.
Zimm said it had been working on developing a drug to treat spinal cord injury for about a year and had found a company that had developed it, but it was not a “significant partner” in the project.
The Zimmer team had raised more than $1 million to help fund the trial, but none of the money was used to fund the drug development, he wrote in a blog post.ZIM also is developing a new class of drugs called non-invasive, non-toxic therapeutic agents that would target tumors, he noted.
Zim has developed a number of these agents and hopes to test them in people soon.